| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2005;28:461-466
© 2005 Elsevier Science NL
Original articles |
a Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, USA
b Department of Pathology and Developmental Biology, Stanford University Medical School, USA
c Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany
Received 25 October 2004; received in revised form 21 February 2005; accepted 9 March 2005.
* Corresponding author. Address: THG-Chirurgie, Medizinische Hochschule Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany. Tel.: +49 511 532 0; fax: +49 511 532 5404. (Email: kofidis{at}thg.mh-hannover.de; tkofidis{at}stanford.edu).
Abstract
Objective: The in vivo immunogenicity of Embryonic Stem Cells is controversial. At present, there is only in vitro evidence of MHC I expression by this cell population but vivid speculation about their immune-privileged state. The immunology aspect of ESC transplantation deserves thorough investigation. Methods: We injected mouse ESC (expressing Green Fluorescent Protein, GFP) into injured myocardium of syngeneic, allogeneic and SCID recipients. Furthermore, we monitored host response for up to 4 weeks post cell transfer. We determined local response (CD 3, CD 11c expression by host cells), MHC I expression by donor cells, MHC-II expression within and around the graft, humoral response of allogeneic hosts using Flow Cytometry and evaluated the hosts' cytokine response using stimulated spleenocytes by means of ELISPOT. Cell survival was estimated by morphometry, by calculating the area of the GFP+ graft over the area of infarction at multiple sections of the harvested heart. Results: There was significant cellular infiltration into and around the graft consisting of T-lymphocytes (CD3+) and dendritic cells (CD 11c). Infiltration was detectable at 1 week and progressed through 4 weeks following cell transplantation. The humoral Ab response was moderate at 2 weeks but frank at 4 weeks. ELISPOT demonstrated a Th1 pathway of donor specific T-lymphocyte response with strong IFN-
and Il-2 production (figure A). MHC I expression was significant within the graft and maximal in the allogeneic groups. Conclusions: An immune response against transplanted ESC was demonstrated and the future use of ESC will likely require the use of systemic immunosuppression.
Key Words: Stem cells • Myocardial repair • Ischemic cardiomyopathy
This article has been cited by other articles:
|
|
 |
|
  W. B. Tabayoyong, J. G. Salas, S. Bonde, and N. Zavazava HOXB4-Transduced Embryonic Stem Cell-Derived Lin-c-kit+ and Lin-Sca-1+ Hematopoietic Progenitors Express H60 and Are Targeted by NK Cells J. Immunol., November 1, 2009; 183(9): 5449 - 5457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. van Laake, R. Hassink, P. A. Doevendans, and C. Mummery Heart repair and stem cells J. Physiol., December 1, 2006; 577(2): 467 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Anversa, J. Kajstura, A. Leri, and R. Bolli Life and Death of Cardiac Stem Cells: A Paradigm Shift in Cardiac Biology Circulation, March 21, 2006; 113(11): 1451 - 1463. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kofidis, D. R. Lebl, R.-J. Swijnenburg, J. M. Greeve, U. Klima, J. Gold, C. Xu, and R. C. Robbins Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Eschenhagen and W. H. Zimmermann Engineering Myocardial Tissue Circ. Res., December 9, 2005; 97(12): 1220 - 1231. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
